Corcept Therapeutics Incorporated CORT
73.35 USD -1.68 (-2.23%)
At closeNov 10, 2026, 4:00 PM EST
73.35 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
71.57 Day range 76.50
28.66 52-week range 126.38
- YTD
- +110.78%
- 1 year
- -2.83%
News
defenseworld.net Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock Now Rated “Moderate Buy” by Wall Street Analysts Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight ratings firms that are currently covering the firm, MarketBeat.com…
benzinga.com Top 3 Health Care Stocks You'll Regret Missing In Q4 Healthcare stocks Alnylam, Madrigal and Corcept appear oversold, with RSI near or below 30, offering potential opportunities for investors.
benzinga.com Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $173 Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics (NASDAQ:CORT) with a Overweight and raises the price target from $165 to $173.
zacks.com CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues Corcept's Q3 earnings and revenues beat estimates, driven by strong Lifyorli uptake and higher Korlym sales, as the company advances its pipeline.
benzinga.com Corcept Therapeutics Q3 2026 Earnings Call Transcript Corcept Therapeutics (NASDAQ:CORT) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Corcept Therapeutics Affirms FY2026 Sales Guidance of $1.100B-$1.200B vs $1.146B Est Corcept Therapeutics (NASDAQ:CORT) affirms FY2026 sales outlook from $1.100 billion-$1.200 billion to $1.100 billion-$1.200 billion vs $1.146 billion estimate.
benzinga.com Corcept Reports Favorable Survival and Response Data in Ovarian Cancer Study Corcept Therapeutics reported positive Phase 2 BELLA trial data for Lifyorli and chemotherapy in platinum-resistant ovarian cancer patients.
benzinga.com Corcept Therapeutics Announces Results From Part A Of Its Phase 2 BELLA Trial Of Lifyorli In Combination With Nab-Paclitaxel And Bevacizumab In Patients With Ovarian Cancer; Lifyorli In Combination With Nab-Paclitaxel And Bevacizumab Demonstrated Clinically Meaningful Progression-Free Survival, Objective Response Rate And Overall Survival Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic…
benzinga.com Oil Tops $100 on Iran Fears, Energy ETF XLE Hits New Record: Stock Market Today WTI crude rose above $100 on fears of renewed U.S. strikes on Iran, lifting XLE to a record while staples, telecoms and the Dow slipped at midday Friday.